Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study will assess efficacy, safety and tolerability of agomelatine (AGO178) 25 mg and 50
mg in patients with Major Depressive Disorder (MDD). This study includes an 8-week
double-blind phase and a 52-week open-label phase.